Prevalence of Brain Lesions on MRI in Girls With Central Precocious Puberty
Pathological brain lesions are not common on MRI in girls with central precocious puberty in the absence of signs or symptoms of CNS lesions.
Central Precocious Puberty
Leuprolide Acetate Approved for Central Precocious Puberty
The FDA has approved Fensolvi (leuprolide acetate; Tolmar Pharmaceuticals) for the treatment of pediatric patients 2 years of age and older with central precocious puberty.
Preexisting Medical Conditions Provide Insight Into Precocious Puberty
The association between precocious puberty and a wide range of preexisting medical conditions could provide additional insight into factors contributing to early pubertal onset.
Prevalence of Nonclassical Congenital Adrenal Hyperplasia in Girls With Central Precocious Puberty
Among girls with true central precocious puberty referred to a tertiary center in Israel, nonclassical congenital adrenal hyperplasia was diagnosed in almost 5% of patients.
Following Approval, Triptorelin 6-Month Injection Now Available to Treat Central Precocious Puberty
Gonadotropin-releasing hormone (GnRH) agonist Triptodur treats central precocious puberty via intramuscular injection.
FDA: Triptorelin Slows Central Precocious Puberty
Data from a phase 3 clinical trial found that triptorelin achieved positive results in patients age 2 and older with central precocious puberty.
Precocious Puberty More Common in Girls Than Boys
Ovarian cyst and McCune-Albright syndrome were most responsible for the increased risk of non-congenital adrenal hyperplasia gonadotropin-independent precocious puberty.
Longer-Term Histrelin Safe, Effective for Central Precocious Puberty
Long-term treatment with the histrelin implant safely and effectively sustained gonadotropin suppression and improved predicted adult height in central precocious puberty.
-
Loading...
-
Loading...
Next post in Pediatric Endocrinology
